Abstract

The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer’s disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.

中文翻译：

---

在 COVID-19 时代最大限度地提高阿尔茨海默病流体生物标志物研究的安全性。

摘要

2019 年冠状病毒病 (COVID-19) 大流行导致世界各地的许多阿尔茨海默病 (AD) 研究突然停止。对于需要面对面接触的研究尤其如此，例如收集生物流体的研究。由于 COVID-19 可能会在很长一段时间内保持威胁，因此液体生物标志物研究的恢复需要制定和实施程序，以最大限度地减少亲自访问参与者、工作人员和处理生物液体样本的个人的风险。需要考虑的一些问题包括构建访问工作流程以尽量减少接触并促进社交距离；对参与者和工作人员进行 COVID-19 筛查和/或检测；戴口罩并保持手部卫生；处理、储存和分析生物流体的预防措施。